All Programs

Use the tool below to view all available Global Neurology Academy Series

Reviewing the Revised Alzheimer’s Diagnostic Criteria: The Role of Biomarkers
Reviewing the Revised Alzheimer’s Diagnostic Criteria: The Role of Biomarkers
NeuroFrontiers
Reviewing the Revised Alzheimer’s Diagnostic Criteria: The Role of Biomarkers
- Clifford Jack Jr., MD
Diagnosing Myasthenia Gravis: The Impact of Social Media
Diagnosing Myasthenia Gravis: The Impact of Social Media
Clinician's Roundtable
Diagnosing Myasthenia Gravis: The Impact of Social Media
- Ashley Baker, MSN, PMHNP
- Vishnu Pandurangadu, MD/MBA, FACEP
- Pritikanta Paul, MD
Zilucoplan: A Promising Potential Treatment for Myasthenia Gravis
Zilucoplan: A Promising Potential Treatment for Myasthenia Gravis
NeuroFrontiers
Zilucoplan: A Promising Potential Treatment for Myasthenia Gravis
Bridging the Gap to Improved Schizophrenia Treatment Options
Bridging the Gap to Improved Schizophrenia Treatment Options
NeuroFrontiers
Bridging the Gap to Improved Schizophrenia Treatment Options
Personalizing Care Plans for Schizophrenia Patients: Key Factors to Consider
Personalizing Care Plans for Schizophrenia Patients: Key Factors to Consider
NeuroFrontiers
Personalizing Care Plans for Schizophrenia Patients: Key Factors to Consider
- Ashley Baker, MSN, PMHNP
- Desiree Matthews, PMHNP-BC
- Rakesh Jain, MD, MPH
Comprehensive Care: Navigating Neurobehavioral Issues in DMD Patients
Comprehensive Care: Navigating Neurobehavioral Issues in DMD Patients
NeuroFrontiers
Comprehensive Care: Navigating Neurobehavioral Issues in DMD Patients
- John F. Brandsema, MD
Researching the Overlap: Hepatic Encephalopathy and Dementia in Focus
Researching the Overlap: Hepatic Encephalopathy and Dementia in Focus
NeuroFrontiers
Researching the Overlap: Hepatic Encephalopathy and Dementia in Focus
- Charles Turck, PharmD, BCPS, BCCCP
- Jasmohan Bajaj, MD
The Impact of a Cholesterol-Lowering Medication on Alzheimer's Disease
The Impact of a Cholesterol-Lowering Medication on Alzheimer's Disease
NeuroFrontiers
The Impact of a Cholesterol-Lowering Medication on Alzheimer's Disease
- Charles Turck, PharmD, BCPS, BCCCP
- Dr. Robert J. Shmookler Reis, PhD
- Dr. Srinivas Ayyadevara, PhD
Case Concepts in Generalized Myasthenia Gravis: Balancing the Need for Glucocorticoids and Integrating FcRn Inhibitors Into Treatment Plans
Case Concepts in Generalized Myasthenia Gravis: Balancing the Need for Glucocorticoids and Integrating FcRn Inhibitors Into Treatment Plans
CME/CE
Case Concepts in Generalized Myasthenia Gravis: Balancing the Need for Glucocorticoids and Integrating FcRn Inhibitors Into Treatment Plans
1.00 credit
- Michael Erdman, PharmD, BCCCP
- Ali A. Habib, MD
1.00 credit
Evaluating Endocrine Complications in DMD Patients: Findings from a Survey
Evaluating Endocrine Complications in DMD Patients: Findings from a Survey
NeuroFrontiers
Evaluating Endocrine Complications in DMD Patients: Findings from a Survey
- Charles Turck, PharmD, BCPS, BCCCP
- Nadia Merchant, MD
- Melody Shi, MD
- Despoina Galetaki, MD
Optimizing Nutritional Support for Patients with Duchenne Muscular Dystrophy
Optimizing Nutritional Support for Patients with Duchenne Muscular Dystrophy
NeuroFrontiers
Optimizing Nutritional Support for Patients with Duchenne Muscular Dystrophy
The Silent Struggle: Understanding ADHD's Impact on Girls and Women
The Silent Struggle: Understanding ADHD's Impact on Girls and Women
NeuroFrontiers
The Silent Struggle: Understanding ADHD's Impact on Girls and Women
- Kathleen Nadeau, PhD
Reviewing the Treatment Landscape for Duchenne Muscular Dystrophy
Reviewing the Treatment Landscape for Duchenne Muscular Dystrophy
NeuroFrontiers
Reviewing the Treatment Landscape for Duchenne Muscular Dystrophy
- Charles Turck, PharmD, BCPS, BCCCP
- Kay Davies, PhD, DBE FMedSci FRS
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credit
- Craig M. McDonald, MD
- Crystal Proud, MD
- Aravindhan Veerapandiyan, MD
1.00 credit
Understanding the Cardiovascular Risks of ADHD Medications
Understanding the Cardiovascular Risks of ADHD Medications
NeuroFrontiers
Understanding the Cardiovascular Risks of ADHD Medications
On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management
On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management
CME/CE
On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management
1.00 credit
- Robert Shin, MD, FANA, FAAN
- Enrique Alvarez, MD, PhD
- Jiwon Oh, MD, PhD, FRCPC
1.00 credit

All Programs

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

All Programs

Popular

Title

Share on ReachMD